Nicholas Pappas
Cardiovascular Disease · Metairie, LANPI 1912079120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,129 and has fallen 98.4% since, to $35 in 2022. That places this record below the midpoint for cardiovascular disease clinicians in LA, where the typical reported total is $3,225.
Across 221 payments — averaging $13.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$435
- Pfizer$393
- Johnson & Johnson$352
- Sanofi-aventis U.S. LLC$263
- E.r. Squibb & Sons, L.L.C.$203
- Amgen$203
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,90499%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $435 |
| Pfizer | 46 | $393 |
| Johnson & Johnson | 28 | $352 |
| Sanofi-aventis U.S. LLC | 19 | $263 |
| E.r. Squibb & Sons, L.L.C. | 13 | $203 |
| Amgen | 17 | $203 |
| Abiomed | 6 | $150 |
| Amarin Pharma, Inc. | 11 | $148 |
| Regeneron Healthcare Solutions, Inc. | 10 | $126 |
| Boehringer Ingelheim | 8 | $121 |
| AstraZeneca | 5 | $96 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $84 |
| Actelion Pharmaceuticals US, Inc. | 4 | $74 |
| Gilead | 5 | $68 |
| Esperion Therapeutics, Inc. | 2 | $55 |
| Bayer | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Terumo Medical Corporation | 2 | $31 |
| Sanofi | 1 | $19 |
| United Therapeutics Corporation | 1 | $14 |
| Medtronic | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,945 in reported general payments places this provider in the 45th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Metairie
- Homeyar DinshawMetairie$14K
- Kamran KhoobehiMetairie$12K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
- Darrell SoletMorgan City$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.